跳至主要内容
临床试验/IRCT20201004048922N1
IRCT20201004048922N1招募中3 期

Evaluation of the effectiveness of intravenous infusion of human COVID-19 hyperimmune plasma with specific antibody titer in hospitalized patients with Covid-19: a randomized clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 75 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Confirmed or suspected COVID-19 pneumonia based on PCR or pulmonary imaging;
  • Presenting clinical symptoms of COVID-19 (fever, cough, dyspnea);
  • O2 saturation equal or less than 93%;
  • Age equal or more than 18 years old;
  • The patient has informed and free written consent to participate in the study;
  • Less than 7 days passed from the onset of clinical symptoms to the time of enrollment;
  • The patient should not attend another clinical trial at the same time.

排除标准

  • Advanced renal or liver disease;
  • Active cancer;
  • Known Hypersensitivity reaction to Plasma-derived drugs;
  • The patient may be excluded from the study during the first 48 hours.

研究者

相似试验